Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
IPO Year: 2013
Exchange: NYSE
Website: zoetis.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/25/2024 | $220.00 | Buy | BTIG Research |
1/12/2024 | $195.00 → $215.00 | Buy | Stifel |
12/19/2023 | $230.00 | Buy | Jefferies |
12/7/2023 | $237.00 | Outperform | Exane BNP Paribas |
9/6/2023 | $230.00 | Buy | HSBC Securities |
7/12/2022 | $205.00 | Overweight | Piper Sandler |
3/9/2022 | $232.00 → $208.00 | Neutral | Citigroup |
12/20/2021 | $184.00 → $232.00 | Neutral | Citigroup |
11/18/2021 | $264.00 | Overweight | Morgan Stanley |
11/18/2021 | $40.00 | Overweight | Morgan Stanley |
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 1:05 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our wo
USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, Aug. 19, 2024 /PRNewswire/ -- USA News Group – How we take care of the planet, and the food we eat is rapidly shifting. Back in May, the World Economic Forum addressed how countries are redefining their bioeconomy for the future, with each aiming for sustainable solutions. NGOs around the world are calling for urgent action to accelerate nature-based solutions to tackle global challenges, while the World Bank is encouraging sustainable agriculture, not an end to farming. Behind the scenes, several biotech firms are working on solutions that can help foster these types of goals, including BioVaxys Technolog
Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Quarter 2024 Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for Second Quarter 2024 Reports Adjusted Net Income of $711 Million, or Adjusted Diluted EPS of $1.56, for Second Quarter 2024 Raises Full Year 2024 Revenue Guidance to $9.100 - $9.250 Billion, with Diluted EPS of $5.35 to $5.45 on a Reported Basis, or $5.78 to $5.88 on an Adjusted Basis Increases Full Year 2024 Operational Revenue Growth to 9% to 11% and Full-Year Operational Growth in Adjusted Net I
Zoetis Inc. (NYSE:ZTS) today announced that its Board of Directors has approved a multi-year $6 billion share repurchase program as part of its capital allocation plans. The demand for Zoetis' innovative and market-leading portfolio has enabled the company to execute its disciplined capital allocation strategy by reinvesting in growth opportunities and returning capital to shareholders, while delivering long-term value. "Our consistently strong performance in recent years and long-term business outlook continue to make Zoetis an attractive investment opportunity," said Wetteny Joseph, Executive Vice President and Chief Financial Officer at Zoetis. "This is Zoetis' largest share repurchase
Zoetis Inc. (NYSE:ZTS) will now host its second-quarter 2024 financial results webcast and conference call at 8:00 a.m. (ET) on Tuesday, August 6, 2024, to minimize conflicts with other industry earnings announcements. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. There is no change to the webcasting information. A replay of the webcast will be made available on August 6, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and tr
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 6, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on August 6, 2024. About Zoetis As the world's leading animal health company, Zoetis
Increased colleague-reported volunteer work by 81% to 16,611 hours Through $8.3 million in grants, the Zoetis Foundation supported 28 initiatives impacting 19 countries to advance opportunities for veterinarians and livestock farmers through education, well-being, and livelihood initiatives Brought to market innovative diagnostics, vaccines and parasiticides to support livestock producers' animal health and productivity goals More than 30% of the company's total electricity use was supplied by renewable sources which includes on-site solar arrays installed at seven facilities – moving Zoetis toward its goal to use 100% renewable electricity by 2030 Replaced plastic with paperbo
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the third quarter of 2024. The dividend will be paid on Wednesday, September 4, 2024, to all holders of record of the Company's common stock as of the close of business on Thursday, July 18, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and
Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:40 p.m. CT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world a
Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 12:05 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for ani
10-Q - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
11-K - Zoetis Inc. (0001555280) (Filer)
SD - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
DEFA14A - Zoetis Inc. (0001555280) (Filer)
DEFA14A - Zoetis Inc. (0001555280) (Filer)
For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o
Across the recent three months, 4 analysts have shared their insights on Zoetis (NYSE:ZTS), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Zoetis, presenting an average target of $205.25, a high estimate of $225.00, and a low estimate of $180.00. A negative shift in sentiment
BTIG analyst Mark Massaro initiates coverage on Zoetis (NYSE:ZTS) with a Buy rating and announces Price Target of $220.
Zoetis (NYSE:ZTS) has outperformed the market over the past 10 years by 7.71% on an annualized basis producing an average annual return of 18.4%. Currently, Zoetis has a market capitalization of $81.78 billion. Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,424.03 today based on a price of $179.23 for ZTS at the time of writing. Zoetis's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
Zoetis's (NYSE:ZTS) short percent of float has fallen 9.27% since its last report. The company recently reported that it has 6.25 million shares sold short, which is 1.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impor
Zoetis (NYSE:ZTS) has outperformed the market over the past 10 years by 7.56% on an annualized basis producing an average annual return of 18.39%. Currently, Zoetis has a market capitalization of $80.07 billion. Buying $100 In ZTS: If an investor had bought $100 of ZTS stock 10 years ago, it would be worth $540.64 today based on a price of $175.48 for ZTS at the time of writing. Zoetis's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BEARISH 07/19/24 $28.00 $74.9K 29.5K 5.7K ZTS CALL SWEEP BEARISH 07/19/24 $170.00 $39.
Zoetis's (NYSE:ZTS) short percent of float has fallen 3.79% since its last report. The company recently reported that it has 5.80 million shares sold short, which is 1.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.52 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impo
Zoetis (NYSE:ZTS) has outperformed the market over the past 10 years by 7.14% on an annualized basis producing an average annual return of 18.04%. Currently, Zoetis has a market capitalization of $77.57 billion. Buying $100 In ZTS: If an investor had bought $100 of ZTS stock 10 years ago, it would be worth $520.85 today based on a price of $170.00 for ZTS at the time of writing. Zoetis's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
https://globalnews.ca/news/10547712/bird-flu-death-mexico-h5n2/#:~:text=It%20started%20on%20April%2017,to%20complications%20of%20his%20condition.
Zoetis's (NYSE:ZTS) short percent of float has risen 16.81% since its last report. The company recently reported that it has 6.03 million shares sold short, which is 1.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.94 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impo
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00
Stifel reiterated coverage of Zoetis with a rating of Buy and set a new price target of $215.00 from $195.00 previously
Jefferies resumed coverage of Zoetis with a rating of Buy and set a new price target of $230.00
Exane BNP Paribas initiated coverage of Zoetis with a rating of Outperform and set a new price target of $237.00
HSBC Securities initiated coverage of Zoetis with a rating of Buy and set a new price target of $230.00
Piper Sandler initiated coverage of Zoetis with a rating of Overweight and set a new price target of $205.00
Citigroup reiterated coverage of Zoetis with a rating of Neutral and set a new price target of $208.00 from $232.00 previously
Citigroup reiterated coverage of Zoetis with a rating of Neutral and set a new price target of $232.00 from $184.00 previously
Morgan Stanley initiated coverage of Zoetis with a rating of Overweight and set a new price target of $264.00
Morgan Stanley initiated coverage of Zoetis with a rating of Overweight and set a new price target of $40.00
Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand
Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide. Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world
Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023. Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences with top tier pharmaceutical companies. Ester will be a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230709430714/en/Ester Banque joins Zoetis as Executive Vice President and President, U.S. Operations, effective July 10, 2023. Source: Zoetis "We are excited to welcome
Johnson & Johnson executive brings valuable business leadership, consumer insights and direct-to-consumer advertising experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs at Johnson & Johnson, to its Board of Directors. Ms. Broadhurst has deep experience in consumer insights and direct-to-consumer advertising, and her appointment increases the size of the Board from 11 to 12 members. She will serve on the Board's Quality and Innovation Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005781/en/Vanessa Broadhurst,
Dr. Catherine Knupp Culminates Remarkable Career of Advancing Animal Care with Breakthrough New Products and Continuous Innovations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Robert J. Polzer, PhD, as Executive Vice President and President of Research & Development for the company, effective Jan. 1, 2022. Polzer currently serves as Senior Vice President of Global Therapeutics for Zoetis and joined the company in 2015 after spending more than 20 years in R&D leadership roles at Pfizer. Polzer will become a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. This press release features multimedia. View the full release here: https://www.busi
Reports Revenue of $1.9 Billion, Growing 22%, and Net Income of $559 Million, or $1.17 per Diluted Share, Increasing 32% and 33%, Respectively, on a Reported Basis for First Quarter 2021 Reports Adjusted Net Income of $603 Million, or Adjusted Diluted EPS of $1.26, for First Quarter 2021 Delivers 21% Operational Growth in Revenue and 34% Operational Growth in Adjusted Net Income for First Quarter 2021 Increases Full Year 2021 Revenue Guidance to $7.500 - $7.625 Billion and Diluted EPS of $4.08 - $4.19 on a Reported Basis, or $4.42 - $4.51 on an Adjusted Basis Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2021 and increased its guidance for ful
Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Quarter 2024 Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for Second Quarter 2024 Reports Adjusted Net Income of $711 Million, or Adjusted Diluted EPS of $1.56, for Second Quarter 2024 Raises Full Year 2024 Revenue Guidance to $9.100 - $9.250 Billion, with Diluted EPS of $5.35 to $5.45 on a Reported Basis, or $5.78 to $5.88 on an Adjusted Basis Increases Full Year 2024 Operational Revenue Growth to 9% to 11% and Full-Year Operational Growth in Adjusted Net I
Zoetis Inc. (NYSE:ZTS) today announced that its Board of Directors has approved a multi-year $6 billion share repurchase program as part of its capital allocation plans. The demand for Zoetis' innovative and market-leading portfolio has enabled the company to execute its disciplined capital allocation strategy by reinvesting in growth opportunities and returning capital to shareholders, while delivering long-term value. "Our consistently strong performance in recent years and long-term business outlook continue to make Zoetis an attractive investment opportunity," said Wetteny Joseph, Executive Vice President and Chief Financial Officer at Zoetis. "This is Zoetis' largest share repurchase
Zoetis Inc. (NYSE:ZTS) will now host its second-quarter 2024 financial results webcast and conference call at 8:00 a.m. (ET) on Tuesday, August 6, 2024, to minimize conflicts with other industry earnings announcements. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. There is no change to the webcasting information. A replay of the webcast will be made available on August 6, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and tr
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 6, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on August 6, 2024. About Zoetis As the world's leading animal health company, Zoetis
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the third quarter of 2024. The dividend will be paid on Wednesday, September 4, 2024, to all holders of record of the Company's common stock as of the close of business on Thursday, July 18, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and
Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Quarter 2024 Delivers 12% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for First Quarter 2024 Reports Adjusted Net Income of $634 Million, or Adjusted Diluted EPS of $1.38, for First Quarter 2024 Updates Full Year 2024 Revenue Guidance to $9.050 - $9.200 Billion, with Diluted EPS of $5.34 to $5.44 on a Reported Basis, or $5.71 to $5.81 on an Adjusted Basis Increases Full Year 2024 Operational Revenue Growth to 8.5% to 10.5% and Full-Year Operational Growth in Adjusted Net I
Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (NASDAQ:PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428775498/en/ Both Zoetis and Phibro Animal Health have a longstanding commitment to the production animal health sector. The acquired product portfolio
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 2, 2024. About Zoetis As the world's leading animal health company, Zoetis is dri
For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Respectively, on a Reported Basis Delivers 8% Operational Growth in Revenue and 6% Operational Growth in Adjusted Net Income for Fourth Quarter 2023 Reports Adjusted Net Income of $569 Million, or Adjusted Diluted EPS of $1.24, for Fourth Quarter 2023 For Full Year 2023, Zoetis Reports Revenue of $8.5 Billion, Growing 6%, and Net Income of $2.3 Billion, or $5.07 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis Delivers 7% Operational Growth in Revenue and Adjusted Net Income for Full Year 20
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the second quarter of 2024. The dividend will be paid on Tuesday, June 4, 2024, to all holders of record of the Company's common stock as of the close of business on Friday, April 19, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock farmers and ranch